SCHEMBL7971741

SCHEMBL7971741

C/C=C/Cn1c(NC2CCNCC2)nc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.61
NR4A2 P43354 1/20 0.61
SSTR5 P35346 3/20 0.43
KAT2B Q92831 1/20 0.43
SOS1 Q07889 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
MKNK1 Q9BUB5 1/20 0.41
HTR3A P46098 1/20 0.40
CYP1A2 P05177 2/20 0.40
HSD17B10 Q99714 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7971742 1.00 KCNH2 (0.61) KCNH2NR4A2SSTR5KAT2BSOS1
SCHEMBL11265895 0.80 KCNH2 (0.83) KCNH2NR4A2SSTR5SOS1HTR3A
SCHEMBL7985049 0.80 KCNH2 (0.65) KCNH2NR4A2SSTR5IRAK4MKNK1
SCHEMBL7981124 0.79 KCNH2 (0.61) KCNH2NR4A2SSTR5KAT2BSOS1
SCHEMBL9534952 0.79 KCNH2 (0.61) KCNH2NR4A2SSTR5CYP1A2HSD17B10
SCHEMBL7494343 0.79 KCNH2 (0.67) KCNH2NR4A2SSTR5SOS1IRAK4
Bromide SCHEMBL11305424 0.79 KCNH2 (0.81) KCNH2NR4A2SSTR5SOS1HTR3A
SCHEMBL6992893 0.79 KCNH2 (0.59) KCNH2NR4A2IRAK4MKNK1CYP1A2
SCHEMBL6991720 0.78 KCNH2 (0.57) KCNH2NR4A2HSD17B10ALDH1A1LMNA
Hydrochloric Acid SCHEMBL5009615 0.77 KCNH2 (0.58) KCNH2NR4A2IRAK4MKNK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6211199-B1 HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS AVENTIS PHARMACEUTICALS INC. 2001-04-03 US disclosed